Craig Hallum Issues Positive Forecast for Delcath Systems (NASDAQ:DCTH) Stock Price

Delcath Systems (NASDAQ:DCTH) had its price target upped by equities researchers at Craig Hallum from $18.00 to $21.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Craig Hallum’s price objective would indicate a potential upside of 50.12% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on the stock. Stephens restated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Delcath Systems in a research report on Tuesday. Canaccord Genuity Group reiterated a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a report on Friday, October 18th. Finally, StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Delcath Systems currently has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Delcath Systems Trading Up 2.3 %

Shares of DCTH stock traded up $0.32 during mid-day trading on Friday, reaching $13.99. The stock had a trading volume of 304,452 shares, compared to its average volume of 471,266. The company has a market cap of $447.23 million, a P/E ratio of -10.40 and a beta of 0.87. Delcath Systems has a 12-month low of $3.70 and a 12-month high of $14.41. The business has a 50-day simple moving average of $11.42 and a 200 day simple moving average of $9.88.

Institutional Investors Weigh In On Delcath Systems

Hedge funds have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Delcath Systems in the third quarter valued at $102,000. Barclays PLC purchased a new stake in Delcath Systems during the third quarter valued at about $104,000. Jane Street Group LLC acquired a new stake in Delcath Systems during the third quarter worth about $110,000. Riverwater Partners LLC purchased a new position in shares of Delcath Systems in the 3rd quarter worth about $161,000. Finally, Virtu Financial LLC purchased a new stake in shares of Delcath Systems during the 3rd quarter worth about $289,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.